Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2015-07-07 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is titled "Genmab Announces European Regulatory Submission for Ofatumumab as Maintenance Therapy for Relapsed CLL" and details the submission of a variation to the Marketing Authorization to the EMA by Novartis on behalf of Genmab. This is a specific announcement regarding regulatory action concerning a drug product, not a comprehensive financial report (like 10-K or IR) or a general earnings release (ER). It is a specific corporate action announcement related to product development and regulatory status. Since there is no specific code for 'Regulatory Submission Announcement' outside of general filings, and this is a formal announcement about a regulatory step, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a material event disclosure that doesn't fit the other specialized financial/governance codes. It is not a Call Transcript (CT), Earnings Release (ER), or a formal financial report (10-K, IR).
2015-07-07 English
Remuneration Information 2015
Remuneration Information Classification · 99% confidence The document is titled "Selskabsmeddelelse" (Company Announcement) and is very short (4396 characters). It announces a specific corporate action: the board's decision to grant 11,100 warrants to employees. This type of announcement, detailing the issuance of stock options/warrants, falls under changes to the capital structure or financing activities. While it relates to employee compensation, the core event is the issuance of securities/options. This aligns best with 'Capital/Financing Update' (CAP) or potentially 'Share Issue/Capital Change' (SHA). Since warrants are a form of capital instrument issuance, SHA is a strong candidate. However, given the context of employee incentive plans, and the general nature of this being a specific, non-routine capital event announcement, CAP is also plausible. Looking closely at the definitions, 'SHA' is for 'New share issues, stock splits, or other capital changes.' Warrants are capital instruments. 'CAP' is for 'fundraising, financing activities, or capital structure changes.' The issuance of employee warrants is a capital structure change. Given the specific nature of the announcement (warrants granted), SHA is slightly more precise than the broader CAP category, which often implies raising external capital. However, since this is a regulatory announcement (Selskabsmeddelelse) about a specific corporate action that changes the potential share count, and it is not a full financial report, I will classify it based on the nature of the security change. Since it is an announcement of a specific corporate action regarding equity instruments, SHA is the most fitting specific code. If SHA were not available, CAP would be the next best fit. Given the document is a direct announcement and not a report about a report, it is not RPA or RNS.
2015-06-11 Danish
Remuneration Information 2015
Remuneration Information Classification · 99% confidence The document is a 'Company Announcement' dated June 11, 2015, stating that the board decided to issue 11,100 warrants to employees. It details the exercise price, vesting schedule, and the warrant plan under which they were granted. This action directly relates to changes in the company's capital structure (issuing equity-linked instruments to employees) and is a form of financing/capital activity. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). Since it is a specific announcement about capital instruments, CAP is more precise than the general 'RNS' fallback.
2015-06-11 English
Regulatory Filings 2015
Regulatory Filings Classification · 100% confidence The document is explicitly titled 'Company Announcement' and details a significant corporate event: Janssen Biotech initiating a rolling submission of a Biologics License Application (BLA) to the U.S. FDA for daratumumab. This is a material update regarding product development and regulatory progress, not a full financial report (like 10-K or IR), a transcript (CT), or a standard earnings release (ER). It is a specific, material announcement that doesn't fit the definitions for AGM-R, MANG, DVA, DLST, DIRS, SR, FS, CGR, IRAT, NAV, DIV, PSI, DEF 14A, TAR, SHA, or POS. Since it is a specific corporate update that is not a standard financial filing, it best fits the general 'Regulatory Filings' (RNS) category as a catch-all for important, non-standard announcements, or potentially 'LTR' if viewed as a regulatory action update, but RNS is the broader fit for general company news releases that aren't financial results or governance documents. Given the context of a biotechnology company announcing a regulatory submission milestone, RNS (Regulatory Filings/General Announcement) is the most appropriate classification.
2015-06-05 English
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is titled "Genmab Announces Start of Rolling Submission of Biologics License Application for Daratumumab for Double Refractory Multiple Myeloma to the FDA" and is explicitly labeled as a "Company Announcement." It details the initiation of a regulatory submission (BLA) to the FDA by a licensing partner (Janssen). This type of announcement, which communicates a specific corporate action related to regulatory filings or clinical progress, fits best under the general category of Regulatory Filings (RNS) or potentially a specific announcement type if one were available for regulatory milestones. Since there is no specific code for 'Regulatory Submission Announcement' and it is not a full financial report (10-K, IR) or an earnings release (ER), RNS serves as the most appropriate general regulatory announcement category. The document length (8965 chars) is substantial, but the content is purely an announcement of a regulatory event, not the regulatory filing itself.
2015-06-05 English
Regulatory Filings 2015
Regulatory Filings Classification · 100% confidence The document is titled "Selskabsmeddelelse" (Company Announcement) and details a specific business event: an exclusive license agreement for antibodies against CD19 from Bristol-Myers Squibb, including a one-time payment. This is a material corporate event announcement, not a full financial report (like 10-K or IR), a transcript (CT), or a formal proxy/voting document. It is a specific regulatory disclosure common in European markets, often equivalent to a press release announcing a significant transaction or development. Given the options, it most closely aligns with a general regulatory announcement that doesn't fit a more specific category like M&A (TAR) or Capital Change (CAP). Since it is a formal, dated announcement of a material event, and it is not explicitly an Earnings Release (ER) or a notice of a report publication (RPA), the most appropriate general category for significant, non-standard corporate news is Regulatory Filings (RNS). The length (5022 chars) is substantial enough to be the primary document, not just a brief RPA.
2015-06-02 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.